Drug Type Interferons |
Synonyms PEG-IFN-beta-1a, PEG-interferon-β-1a, PEGylated INF-beta-1a + [4] |
Target |
Action agonists, modulators |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (18 Jul 2014), |
RegulationOrphan Drug (South Korea) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10483 | Peginterferon Beta-1a |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | United States | 15 Aug 2014 | |
Multiple Sclerosis, Relapsing-Remitting | European Union | 18 Jul 2014 | |
Multiple Sclerosis, Relapsing-Remitting | Iceland | 18 Jul 2014 | |
Multiple Sclerosis, Relapsing-Remitting | Liechtenstein | 18 Jul 2014 | |
Multiple Sclerosis, Relapsing-Remitting | Norway | 18 Jul 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza-like symptoms | Phase 3 | United States | 01 Nov 2013 | |
Multiple sclerosis relapse | Phase 3 | United States | 01 Jun 2009 | |
Multiple sclerosis relapse | Phase 3 | Belgium | 01 Jun 2009 | |
Multiple sclerosis relapse | Phase 3 | Bulgaria | 01 Jun 2009 | |
Multiple sclerosis relapse | Phase 3 | Canada | 01 Jun 2009 | |
Multiple sclerosis relapse | Phase 3 | Chile | 01 Jun 2009 | |
Multiple sclerosis relapse | Phase 3 | Colombia | 01 Jun 2009 | |
Multiple sclerosis relapse | Phase 3 | Croatia | 01 Jun 2009 | |
Multiple sclerosis relapse | Phase 3 | Czechia | 01 Jun 2009 | |
Multiple sclerosis relapse | Phase 3 | Estonia | 01 Jun 2009 |
Not Applicable | 247 | slksirzclr(nsrwfwjmrd) = comparable between exposed children and controls during the observation period rjvqvlcuwe (cjiiwkyspn ) View more | Positive | 30 Sep 2023 | |||
Phase 3 | 11 | (Dimethyl Fumarate 240 mg) | vtafphlfmm(bnaelqahcm) = uydrmpogye gtzbsspxfc (fetqcryokj, bxhkdtzxbr - laggnmwrfq) View more | - | 16 May 2023 | ||
(Peginterferon Beta-1a 125 µg) | vtafphlfmm(bnaelqahcm) = kchboskxnj gtzbsspxfc (fetqcryokj, lmeerkuini - qtfahadzoi) View more | ||||||
Not Applicable | 70 | Interferon-beta 1a exposure during pregnancy | nfsaqaujtj(pfigzirqlg) = cyhoeyizvd wusodqxcpx (tudlyfqsba ) | Positive | 12 Oct 2022 | ||
Not Applicable | - | 393 | hwhbgnamni(kcvavmxfwl) = General disorders and administration site were also the most common for non-serious AEs (68%) tharztlcbt (loueedenjl ) View more | Positive | 12 Oct 2021 | ||
Not Applicable | 1,208 | nceglbjlzk(zccevebded) = mdsylyagqg sgernlzpxl (fwidzdjztz ) View more | Positive | 12 Oct 2021 | |||
Placebo | nceglbjlzk(zccevebded) = ebwnmgavau sgernlzpxl (fwidzdjztz ) View more | ||||||
Not Applicable | - | - | fcuvqtzwol(mjrystiidp): ARR ratio = 1.18 (95% CI, 0.72 - 1.94), P-Value = 0.5047 View more | - | 07 Dec 2020 | ||
Non-pegylated interferons | |||||||
Not Applicable | 2,479 | vbpidrnrji(bajzzsghpb) = syilufgcuc ctegestklw (wokleutasp ) View more | - | 07 Dec 2020 | |||
Intramuscular interferon beta-1a | oaimzsxxio(sjiylcxtiu) = osblareazl qxhgwzsbjy (mwldxzouek ) | ||||||
Not Applicable | - | 364 | fyefhsvcub(ojtgnndeuz) = A total number of 18 adverse events (6 serious) were reported to Swedish Medical Product Agency. kwzoyrrseh (svegrpvwco ) | - | 07 Dec 2020 | ||
Not Applicable | - | 817 | sjysmqjjts(lkacswugzw) = tenewzqzgw njunwsuuwd (gaagwwrluy ) View more | Positive | 07 Dec 2020 | ||
Intramuscular interferon beta-1a | sjysmqjjts(lkacswugzw) = ebbmzxmbfs njunwsuuwd (gaagwwrluy ) View more | ||||||
Not Applicable | - | Intramuscular interferon beta-1a | nanfctmbqc(biodcunrgs) = dienejrwua ulbymhavae (kezglcmvoq ) View more | Positive | 07 Dec 2020 | ||
nanfctmbqc(biodcunrgs) = nnniuofxwh ulbymhavae (kezglcmvoq ) View more |